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Abstract
Background:  We investigated if global gene expression and transcription networks in B-
lymphocytes of siblings with multiple sclerosis (MS) were different from healthy siblings.
Results: Using virus-transformed immortalized B cells and human whole genome bioarrays with
validation using RT-qPCR, we found that in siblings with MS, genes for CXCL10, serpin B1 and
FUT4 were up regulated whereas CDC5L, TNFRSF19 and HLA-DR were down regulated, among
others; transcription analysis showed two intersecting clusters of transcriptional factors - the
larger, governed by the upregulated transcription factor 2 (TCF2) and the smaller network
regulated by the downregulated CDC5L.
Conclusion: No study has linked TCF2 to MS and to better understand the role of TCF2 in MS,
studies in larger cohorts are required.
Background
MS is a complex genetic disease associated with inflam-
mation predominantly in the white matter of brain and
spinal cord. It is thought to be mediated by autoreactive T
cells [1,2]. Susceptibility to MS is determined by both
inherited and non-inherited factors [3]. Approximately
15-20% of MS patients have a family history of MS, but
large extended pedigrees are uncommon. Studies in twins
[4,5] and conjugal pairs [6] show that much of the famil-
ial clustering is the result of shared genetic risk factors.
MS susceptibility is linked to HLA-DR2 [7]. Increased risk
of MS in women has been detected with interleukin-1
receptor antagonist (IL-1RA) allele 2 [8], 5G5G genotype
of plasminogen activator inhibitor 1 (PAI-1) gene [9] and
interaction between estrogen receptor 1 (ESR1) and HLA-
DR2 [10]. B cells are implicated in MS and have been
found in the cerebrospinal fluid (CSF) of MS patients
[11]. Additionally, oligoclonal bands identified in CSF
point to the role of B cells in MS pathogenesis [12]. Fur-
thermore, antibody-secreting B cells contribute to tissue
injury [13]. We hypothesized that B cells derived from MS
patients could harbor genes that confer a higher MS risk as
compared to B cell gene expression in healthy siblings.
Human B-cells have a receptor for Epstein-Barr virus
(EBV) and can become immortalized after in vitro infec-
tion with EBV. Additionally, the link between EBV and MS
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is highly impressive [14] though inconclusive; we hypoth-
esized that analysis of gene expression and transcription
networks in EBV-transformed B cells between siblings
with and without MS could yield important clues to
understanding the pathology of MS.
Large-scale analyses of transcripts from peripheral blood
cells or brain lesions from MS patients have created possi-
bilities for therapeutics [15] and global gene expression
analysis using microarrays is a sensitive method to inves-
tigate molecular heterogeneity [16]. In this study, we
tested a new software tool that is in development, to map
transcription networks in the microarray data.
Our objectives were to i) to determine if gene expression
and transcription networks in B-lymphocytes of siblings
with MS were different from healthy siblings in EBV-trans-
formed B cells and ii) to validate data using qPCR tech-
niques.
Methods
EBV-transformed B cell lines from Coriell Institute for
medical research (Camden, NJ, USA) and the National
Institute of General Medical Sciences (NIGMS, Bethesda,
MD) were obtained for our study. As shown in Table 1, B
cells were harvested from one family (# 2108, proband,
affected sister) and an unaffected brother (control); cells
from another family (# 2112, proband, affected brother)
and three unaffected brothers (controls). Cells from the
third family (# 2102) comprised of proband and an
affected sister but no unaffected controls. None of the
patients were on immunomodulatory agents (IMAs) to
treat MS.
Cells were harvested in 4 ml of Tri-Reagent (Molecular
research center, Inc) and the total RNA was isolated using
standard protocols. Briefly, B-cells were incubated at 37°C
and 5% CO2 overnight, the day after cells were counted.
Cells were expanded in RPMI 1640 with 2 mM L-
glutamine and 15% fetal bovine serum following Coriell's
lymphoblast line maintenance protocols. 2 vials were fro-
zen and 1 × 107 cells were spun down and resuspended in
2 ml of Tri-reagent. The cell mixture was frozen at -80°C
until further analysis. The RNA was isolated using the
standard Tri-reagent protocol and further cleaned up
using RNeasy kits (Qiagen) using a protocol that included
an on column Dnase step. RNA samples were checked for
quality on a Bioanalyzer and a nanodrop spectrophotom-
eter. Samples with 28s/18s ratio > 1.8 were deemed
acceptable for the microarray experiment. The total RNA
(1 ug) was first converted to double stranded cDNA using
the standard Codelink protocol. This was then purified on
Qiaquick PCR columns and in vitro transcribed to labeled
cRNA using biotin-11-UTP (Perkin Elmer). The labeled
cRNA was purified on Qiagen RNeasy Mini columns and
10 ug was fragmented as per the Codelink protocol fol-
lowing which it was hybridized to the Codelink Human
Whole Genome bioarrays for 18 h at 37°C. The arrays
were subsequently washed, stained with Cy5-Streptavidin
(GE Amersham) and scanned on an Axon Genepix 4000B
scanner. The data were collected using Codelink Expres-
sion Analysis software and analyzed using Genespring
software version 7.3.1 (Agilent). All microarray data are
deposited at Gene Expression Omnibus as GSE 10064 and
linked via [17].
Microarray data analysis
Values below 0.01 were set to 0.01. Each measurement
was divided by the 50th percentile of all measurements in
that sample. All samples were normalized to the median
of the control samples. Each measurement for each gene
in those specific samples was divided by the median of
that gene's measurements in the corresponding control
samples. The gene list (54,902 transcripts) was filtered
using the cross gene error model for replicates to select
genes with good signal-to-noise ratios (31, 168 genes).
This gene list was subjected to a student's t-test (p-value <
0.05) and yielded 1, 417 genes with significant differences
between the two conditions. This list was further filtered
for confidence using a Benjamini-Hochberg false discov-
ery rate correction to obtain 1405 genes. A 1.5-fold cut-off
filter was then applied to identify genes that were prefer-
Table 1: Cell lines obtained from Corielle for our study.
Sample ID Relation Family Affected Sex Age
GM8923 Proband 2108 Yes Male 38
GM8922A Sister 2108 Yes Female 43
GM8830 Proband 2102 Yes Female 47
GM8839 Sister 2102 Yes Female 39
GM9013 Proband 2112 Yes Male 35
GM9016 Brother 2112 Yes Male 38
GM9018 Brother 2112 No Male 42
GM9017 Brother 2112 No Male 45
GM9023 Brother 2112 No Male 47
GM8921A Brother 2108 No Male 46BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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entially upregulated (260) or downregulated (452) genes
in samples with disease as compared to controls. These
712 genes were further filtered to only select those which
were consistently 'absent" or "present" in 3 of 4 controls
and 5 of 6 diseased samples. The final gene list had 705
genes; 259 upregulated and 446 downregulated genes
while using 2-fold cut off resulted in 84 upregulated and
111 downregulated genes (Tables 2 & 3).
Hierarchical clustering
This gene list was subjected to a hierarchical clustering
routine in GeneSpring using a Pearson correlation similar-
ity measure across conditions and a standard correlation
similarity measure across genes. The final tree is repre-
sented in Figure 1.
Table 2: Representative upregulated genes (out of 259 total).
Probe ID Fold Change Common Genbank Description
Upregulated genes
GE53598 5.88 TINAG NM_014464 tubulointerstitial nephritis antigen, complete cds
GE59642 5.77 CXCL10 NM_001565 gamma-interferon inducible early response gene (with homology to platelet proteins)
GE57550 4.74 CRYM NM_001888 mu-crystallin mRNA, complete cds
GE518123 4.27 IGLL1 NM_020070 immunoglobulin lambda-like polypeptide 1 (IGLL1), transcript variant 1, mRNA
GE58736 4.20 DACT1 NM_016651 dapper homolog 1, antagonist of beta-catenin (xenopus) (DACT1), mRNA
GE79033 4.15 CD9 NM_001769 CD9 antigen (p24) (CD9), mRNA
GE55346 3.57 LRRC16 NM_017640 leucine rich repeat containing 16 (LRRC16), mRNA
GE61239 3.50 SERPINB1 NM_030666 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 (SERPINB1), 
mRNA
GE62781 3.50 MT1F NM_005949 metallothionein 1F (functional) (MT1F), mRNA
GE87501 3.49 FXYD2 NM_001680 FXYD domain containing ion transport regulator 2 (FXYD2), transcript variant a, mRNA
GE61946 3.26 ARHGAP6 NM_001174 Rho GTPase activating protein 6 (ARHGAP6), transcript variant 2, mRNA
GE56932 3.22 EGLN3 NM_022073 egl nine homolog 3 (C. elegans) (EGLN3), mRNA
GE61093 3.18 ACTN1 NM_001102 actinin, alpha 1 (ACTN1), mRNA
GE87626 2.97 OSR2 NM_053001 odd-skipped-related 2A protein (OSR2), mRNA
GE59655 2.93 ATP1B1 NM_001677 ATPase, Na+/K+ transporting, beta 1 polypeptide (ATP1B1), mRNA
GE58575 2.91 PTPLA NM_014241 protein tyrosine phosphatase-like (proline instead of catalytic arginine), member a 
(PTPLA), mRNA
GE57767 2.84 COL9A3 NM_001853 collagen, type IX, alpha 3 (COL9A3), mRNA
GE57621 2.83 LGALS3BP NM_005567 lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), mRNA
GE81389 2.82 CCR6 NM_004367 chemokine (C-C motif) receptor 6 (CCR6), transcript variant 1, mRNA
GE79898 2.81 LYPLA3 NM_012320 lysophospholipase 3 (lysosomal phospholipase A2) (LYPLA3), mRNA
GE62292 2.79 CPXM NM_019609 carboxypeptidase X (M14 family) (CPXM), mRNA
GE57547 2.66 TCN2 NM_000355 transcobalamin II; macrocytic anemia (TCN2), mRNA
GE81525 2.52 IFI27 NM_005532 ISG12 protein
GE79641 2.48 FUT4 NM_002033 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific) (FUT4), mRNA
GE81272 2.47 VIM NM_003380 vimentin (VIM), mRNA
GE57737 2.45 ENPP2 NM_006209 autotaxin mRNA, complete cds
GE80150 2.38 ELF3 NM_004433 E74-like factor 3 (ets domain transcription factor, epithelial-specific) (ELF3), mRNA
GE58207 2.34 ENG NM_000118 endoglin (Osler-Rendu-Weber syndrome 1) (ENG), mRNA
GE57048 2.33 CCR1 NM_001295 chemokine (C-C motif) receptor 1 (CCR1), mRNA
GE57883 2.28 SELL NM_000655 selectin L (lymphocyte adhesion molecule 1) (SELL), mRNA
GE60214 2.27 NRGN NM_006176 neurogranin (protein kinase C substrate, RC3) (NRGN), mRNA
GE498904 2.22 DACT1 NM_016651 dapper homolog 1, antagonist of beta-catenin (xenopus) (DACT1), mRNA
GE81340 2.17 PSTPIP1 NM_003978 proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1), mRNA
GE58931 2.16 TCF8 U12170 zinc finger homeodomain protein mRNA, complete cds
GE61464 2.15 SERPINB9 NM_004155 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9 (SERPINB9), 
mRNA
GE82947 2.12 SNX22 NM_024798 sorting nexin 22 (SNX22), mRNA
GE60134 2.09 UPP1 NM_003364 uridine phosphorylase (UP), transcript variant 1, mRNA
GE54152 2.07 APOL1 NM_003661 apolipoprotein L, 1 (APOL1), transcript variant 1, mRNA
GE56786 2.02 DUSP4 NM_001394 dual specificity phosphatase 4 (DUSP4), transcript variant 1, mRNA
GE54528 2.02 TNFSF12; NM_003809 tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12), transcript variant 1, 
mRNA
GE61789 2.02 TDE2L NM_178865 tumor differentially expressed protein 2 (TDE2), mRNA
GE61399 2.01 LLT1 NM_013269 lectin-like NK cell receptor (LLT1), mRNA
Fold change = diseased/normalBMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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Pathway Analysis
The 1.5 fold list was further analyzed using Onto-Express
and Pathway-Express, part of the Onto-Tools package
available from the Draghici laboratory. This software
allows for identification of pathways that show enrich-
ment in the microarray data and is a novel tool that trans-
lates lists of differentially regulated genes into functional
profiles characterizing the impact of the condition stud-
ied.
Quantitative PCR validation
To verify expression data obtained by the Codelink analysis,
Taqman gene expression assays were obtained (Applied Bio-
systems) to evaluate the expression of selected genes by RT-
qPCR. The assays utilized were as follows: TCF2 (Applied
Biosystems assay Hs01001609_m1), CXCL10
(Hs00171042_m1), FUT4 (Hs00275643_s1), SERPINB1
(Hs00229084_m1), CD9 (Hs01124026_m1), LYPLA3
(Hs00202399_m1), SERPINB9 (Hs00394497_m1), CD83
(Hs00188486_m1), CDC5L (Hs00904622_m1), TNFRSF19
(Hs00218634_m1), HLA-DRA (Hs00219578_m1). All
assays are designed to detect the appropriate transcripts at an
exon-exon junction to ensure the detection of mRNA and
not genomic DNA.
The expression levels of these 11 genes were evaluated by
two-step Taqman-based RT-qPCR. First strand cDNA was
synthesized with M-MLV reverse transcriptase (Ambion,
Inc., Austin, TX) and primed with oligo-dT per the manu-
facturer's specifications. The cDNA equivalent of 20 ng
starting RNA was then included in reactions containing 1×
Taqman Master Mix (Applied Biosystems, Foster City,
CA), and 1× gene-specific assay reagents as recommended
by the manufacturer (Applied Biosystems). All reactions
were run in triplicate. Reactions that did not contain tem-
plate cDNA were included as negative controls.
Reaction plates were processed on an Applied Biosystems
7900 HT Sequence Detection System. The AmpliTaq Gold
polymerase was activated at 95°C for 10 min followed by
Table 3: Representative downregulated genes (out of 446 total)
Probe ID Fold change Common Genbank Description
Down regulated genes
GE54030 0.09 EIF1AY NM_004681 eukaryotic translation initiation factor 1A, Y-linked (EIF1AY), mRNA
GE79500 0.1 RPS4Y NM_001008 ribosomal protein S4, Y-linked (RPS4Y), mRNA
GE54029 0.12 DDX3Y NM_004660 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide, Y chromosome (DBY), mRNA
GE59227 0.12 JARID1D NM_004653 Smcy homolog, Y-linked (mouse) (SMCY), mRNA
GE55836 0.15 MLAT4 NM_018192 myxoid liposarcoma associated protein 4 (MLAT4), mRNA
GE54974 0.19 TNFRSF19 NM_148957 tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), transcript variant 2, 
mRNA
GE788416 0.28 KRTAP4-9 AJ406941 partial mRNA for keratin associated protein 49 (KRTAP4.9 gene)
GE489986 0.32 ZFY NM_003411 zinc finger protein, Y-linked (ZFY), mRNA
GE58359 0.35 GCHFR NM_005258 GTP cyclohydrolase I feedback regulatory protein (GCHFR), mRNA
GE87376 0.36 BAIAP2L1 NM_018842 insulin receptor tyrosine kinase substrate (LOC55971), mRNA
GE561268 0.39 FOXD4L2 NM_199135 FOXD4-like 2 (FOXD4L2), mRNA
GE54486 0.4 DAPK2 NM_014326 death-associated protein kinase 2 (DAPK2), mRNA
GE79999 0.4 CAMK1 NM_003656 calcium/calmodulin-dependent protein kinase I (CAMK1), mRNA
GE58178 0.4 KAL1 NM_000216 Kallmann syndrome (KAL) mRNA, complete cds
GE82446 0.4 BAIAP2L1 NM_018842 insulin receptor tyrosine kinase substrate (LOC55971), mRNA
GE58327 0.41 CD83 NM_004233 CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) (CD83), mRNA
GE567535 0.42 NGFRAP1 AF187064 p75NTR-associated cell death executor (NADE) mRNA
GE62339 0.42 CSE-C NM_018978 sialic acid-specific 9-O-acetylesterase I mRNA, complete cds
GE82815 0.42 FA2H NM_024306 fatty acid 2-hydroxylase (FA2H), mRNA
GE82367 0.44 LAPTM4B NM_018407 lysosomal associated protein transmembrane 4 beta (LAPTM4B), mRNA phosphodiesterase 
4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila)
GE81609 0.45 PDE4A NM_006202 (PDE4A), mRNA
GE61123 0.45 ZNF239 NM_005674 zinc finger protein 239 (ZNF239), mRNA
GE53189 0.46 AUTS2 NM_015570 autism susceptibility candidate 2 (AUTS2), mRNA
GE81426 0.46 USP9Y NM_004654 ubiquitin specific protease 9, Y chromosome (fat facets-like Drosophila) (USP9Y), mRNA
GE63274 0.48 CENTG3 AL537305 FETAL BRAIN cDNA clone CS0DF025YC08 5-PRIME
GE83170 0.48 BCL2L14 NM_030766 apoptosis regulator BCL-G (BCLG), transcript variant 2, mRNA
GE58554 0.49 PRO1914 NM_014106 PRO1914 protein (PRO1914), mRNA
GE86889 0.49 SLC26A7 NM_052832 solute carrier family 26, member 7 (SLC26A7), transcript variant 1, mRNA
GE81520 0.49 BCAT1 NM_005504 branched chain aminotransferase 1, cytosolic (BCAT1), mRNA
Fold change = diseased/normalBMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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40 cycles consisting of denaturation for 15 seconds at
95°C and annealing and extension for 60 seconds at
60°C.
Amplification data was analyzed with the ABI Prism SDS
2.1 software (Applied Biosystems). Although run individ-
ually, samples GM8921A, 9017, 9018, and 9023 were
pooled for analysis as the control sample, and samples
GM8830, 8922A, 8923, 8839, 9013, and 9016 were
pooled for analysis as the MS sample, unless otherwise
noted. Relative quantification of gene expression was per-
formed by the ∆∆Ct method [18]. GAPDH expression was
used as an endogenous control to normalize expression
within each sample.
Transcription network analysis
We employed a software program that one of our authors
continues to develop (G.A.) to recast the matrix of regula-
tory interactions found in a prior step as a directed graph
overlaying color information for gene responses. Our reg-
ulatory network was constructed by integrating transcrip-
tion factor binding site information (from TRANSFAC)
with gene expression data using graph TFs (Bioconductor
functions for transcription network analysis). The stand-
ard microarray experiments cannot measure the transcrip-
tion factor activities (TFAs) directly, since TFAs are subject
to post-translational modifications or ligand binding in
order to exert their function.
We hypothesized that decoding some of the important
TFAs involved in B cells of MS patients might provide
important clues to disease pathogenesis or uncover poten-
tial molecular targets for therapy. We started with an ini-
tial list of all genes changing at the 1.5-fold level. In this
dual sample study, we assumed all pairs of genes moving
in the same direction to be concordant and all pairs mov-
ing in opposite directions to be discordant. Combining
this with the potential for regulatory relationships
inferred from a TRANSFAC binding site dataset, we were
able to extrapolate the potential transcription regulatory
networks driving expression changes. We found that TCF2
and CDC5L bind very similar promoter motifs and seem
to control overlapping sets of up and down regulated
genes in this study. The transcripts we uncovered in this
dataset are most notably, CCR1 and CXCR4, molecules
which are associated with MS. The multiplication of cor-
responding cells in the TFBS and correlation matrices
yields a regulation matrix where the sign of the interaction
score reflects positive or negative regulation and the mag-
nitude of the score reflects the amount of supporting evi-
dence, as shown in the grid below (Figure 2). We
examined these networks for various thresholds of fold-
change and TRANSFAC evidence scores to obtain the pic-
ture of regulation of downstream molecules by tcf2 and
cdcl5 shown in Figure 3.
Hierarchical clustering of all statistically significant genes that  show differential expression between diseased and normal  samples Figure 1
Hierarchical clustering of all statistically significant 
genes that show differential expression between dis-
eased and normal samples. Upregulated are colored red 
and downregulated genes are colored green. Clustering of 
genes is shown on the left while condition based tree is 
shown on the top.
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Results
As shown in Figure 1, the rows represent hierarchical clus-
tering of all differentially expressed genes between the dis-
eased (MS) and control (normal siblings) samples. The
MS samples were 8923, 8922 A, 8830, 8839, 9013 and
9016, respectively. The unaffected siblings were 9017,
9018, 9023 and 8921A, respectively. Onto-Express analy-
ses depicted in Figure 4 shows that transcription factor
binding is a highly significant component in our microar-
ray data. Results from Pathway-Express analysis are listed
in Table 4, and these show that immune function and
neurospecific pathways are also highly implicated in this
data set.
We selected a subset of genes that were up and down reg-
ulated in the MS samples for further validation by RT-
qPCR. Our results generally confirmed the results
obtained with the Codelink arrays. TCF2, CXCL10, and
FUT4 were all up regulated in the MS samples whereas
CDC5L, TNFRSF19 and HLA-DR were down regulated
(Table 5).
For three other genes, we obtained disparate results for
expression when the control and MS samples were pooled
for analysis. CD83 was up regulated by RT-qPCR while
down regulated by array analysis, SERPINB9 was down
regulated by RT-qPCR while up regulated on the arrays,
and CD9 was only minimally up regulated by RT-qPCR
while clearly up regulated on the arrays (Table 6). For each
of these genes, some samples were negative for expression
by RT-qPCR (control sample 8921A for SERPINB9 and
CD9, MS sample 8922A for CD83), and the influence of
the negative values is not fully accounted for when pool-
ing the samples prior to analysis by the ∆∆Ct method.
Thus, for these genes we further evaluated the RT-qPCR
data by analyzing the control and MS samples individu-
ally and then averaging, rather than pooling the samples
prior to the ∆∆Ct analysis. After evaluating individual
samples, we also found that some control samples were
significant outliers for the CD83 and SERPINB9 genes.
Control sample 8921A had a 26-fold increase in CD83
expression relative to the next highest control sample, and
control sample 9018 had a 255-fold increase in SERPINB9
expression and a 156-fold increase in CD9 expression rel-
ative to the next highest samples for those genes (data not
shown). To compensate for these outliers, we eliminated
the highest expression samples from both the control and
MS samples from the analysis and also included the neg-
ative samples. When analyzed in this way, CD83 expres-
sion in the MS samples was down regulated by 0.58-fold,
SERPINB9 expression was up regulated by 2.47-fold, and
Analysis of transcription networks from microarray data Figure 2
Analysis of transcription networks from microarray data.BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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Transcription factor network deciphered from genes differentially expressed at a 1.5 fold cutoff in microarray data Figure 3
Transcription factor network deciphered from genes differentially expressed at a 1.5 fold cutoff in microarray 
data. The color 'red" shows upregulation while "green" shows downregulated expression. Genes are depicted by circles while 
transcription factors are represented as rectangles. Green arrows indicate that the nodes at each end of the arrow are regu-
lated in the same direction (up or down) while the red arrows connect the nodes that are anticorrelated.
A.
B.BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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CD9 expression was up regulated 3.5-fold relative to the
Control samples (Table 6) and these results are in con-
cordance with array data for these genes.
Although we included a Taqman assay for LYPLA3 in our
validation studies, we were not able evaluate expression of
this gene by RT-qPCR. None of the four Control samples
were consistently positive for expression of this gene by
RT-qPCR, and only one of the six MS samples was consist-
ently positive. The probe for this gene on the Codelink
array is located near the 3' end of the coding sequence
whereas the Taqman assay detects sequences at the 5' end
Results from functional profiling of data using Onto-Express Figure 4
Results from functional profiling of data using Onto-Express. (A) The figure shows the significant (red) biological proc-
esses represented in a set of genes differentially expressed between two clinical groups. (B) The figure shows the significant 
(red) molecular function represented in a set of genes differentially expressed between two clinical groups.B
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) Table 4: Results of pathway profiling using Pathway Express.
Rank Database 
Name
Pathway Name Impact Factor #Genes in 
Pathway
#Input Genes in 
Pathway
#Pathway Genes on 
Chip
%Input Genes in 
Pathway
%Pathway Genes in 
Input
p-value
1 KEGG Cell adhesion molecules (CAMs) 6.94 132 11 126 2.099 8.333 9.69E-04
2 KEGG Axon guidance 6.94 130 11 126 2.099 8.462 9.69E-04
3 KEGG Leukocyte transendothelial migration 5.288 117 9 113 1.718 7.692 0.005054
4 KEGG Type I diabetes mellitus 5.232 44 5 40 0.954 11.364 0.005344
5 KEGG Regulation of actin cytoskeleton 4.461 206 12 198 2.29 5.825 0.011556
6 KEGG Natural killer cell mediated cytotoxicity 4.11 128 8 114 1.527 6.25 0.016401
7 KEGG Focal adhesion 3.949 194 11 188 2.099 5.67 0.019276
8 KEGG Tight junction 3.187 119 7 112 1.336 5.882 0.041314
9 KEGG Antigen processing and presentation 3.112 86 5 68 0.954 5.814 0.044499
10 KEGG Adherens junction 2.721 77 5 76 0.954 6.494 0.065823
11 KEGG Colorectal cancer 2.676 77 5 77 0.954 6.494 0.068828
12 KEGG Circadian rhythm 2.386 18 2 18 0.382 11.111 0.091979
13 KEGG Maturity onset diabetes of the young 1.975 25 2 23 0.382 8 0.138816
14 KEGG VEGF signaling pathway 1.972 72 4 70 0.763 5.556 0.139208
15 KEGG Fc epsilon RI signaling pathway 1.83 75 4 74 0.763 5.333 0.160493
16 KEGG mTOR signaling pathway 1.811 49 3 49 0.573 6.122 0.16353
17 KEGG Huntington's disease 1.558 30 2 30 0.382 6.667 0.210455
18 KEGG Wnt signaling pathway 1.474 147 6 144 1.145 4.082 0.229071
19 KEGG MAPK signaling pathway 1.441 273 10 268 1.908 3.663 0.236637
20 KEGG Toll-like receptor signaling pathway 1.416 91 4 88 0.763 4.396 0.242667
21 KEGG B cell receptor signaling pathway 1.318 63 3 63 0.573 4.762 0.267565
22 KEGG T cell receptor signaling pathway 1.294 93 4 93 0.763 4.301 0.274064
23 KEGG Long-term potentiation 1.235 67 3 66 0.573 4.478 0.290928
24 KEGG Insulin signaling pathway 1.143 135 5 131 0.954 3.704 0.318761
25 KEGG Type II diabetes mellitus 1.117 44 2 41 0.382 4.545 0.327167
26 KEGG Dentatorubropallidoluysian atrophy (DRPLA) 1.044 15 1 15 0.191 6.667 0.352194
27 KEGG Epithelial cell signaling in Helicobacter pylori infection 0.997 46 2 45 0.382 4.348 0.368822
28 KEGG Parkinson's disease 0.992 16 1 16 0.191 6.25 0.370684
29 KEGG Cytokine-cytokine receptor interaction 0.963 256 8 241 1.527 3.125 0.381922
30 KEGG Jak-STAT signaling pathway 0.936 153 5 144 0.954 3.268 0.392344
31 KEGG Apoptosis 0.86 84 3 83 0.573 3.571 0.423249
32 KEGG Complement and coagulation cascades 0.6 69 2 64 0.382 2.899 0.548544
33 KEGG Olfactory transduction 0.523 31 1 31 0.191 3.226 0.592482
34 KEGG SNARE interactions in vesicular transport 0.468 36 1 34 0.191 2.778 0.62642
35 KEGG Phosphatidylinositol signaling system 0.421 79 2 78 0.382 2.532 0.656227
36 KEGG Taste transduction 0.317 53 1 45 0.191 1.887 0.728441
37 KEGG GnRH signaling pathway 0.277 97 2 95 0.382 2.062 0.758254
38 KEGG Gap junction 0.27 99 2 96 0.382 2.02 0.763352
39 KEGG Adipocytokine signaling pathway 0.145 69 1 69 0.191 1.449 0.864684
40 KEGG Long-term depression 0.124 75 1 74 0.191 1.333 0.882976
41 KEGG Neuroactive ligand-receptor interaction 0.102 302 5 279 0.954 1.656 0.902917
42 KEGG ECM-receptor interaction 0.086 87 1 86 0.191 1.149 0.91743
43 KEGG Cell cycle 0.042 112 1 110 0.191 0.893 0.958921
44 KEGG Calcium signaling pathway 0.041 176 2 173 0.382 1.136 0.959904BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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of the coding sequence, at the junction between exons 1
and 2 (6 total exons). Thus, full length cDNA would be
required to detect LYPLA3 expression with the Taqman
assay we employed. Our inability to consistently detect
this gene suggests that we did not generate full length
LYPLA3 cDNA during the RT step - either due to mRNA
instability or inefficient reverse transcription.
Additional data
A list of genes at 1.5 fold differential expression from
microarray data can be found in Additional file 1.
Discussion and Conclusion
The genes involved in our analyses encode proteins
involved in apoptosis, cytokine pathways and inflamma-
tion. Although up or downregulation of gene transcrip-
tion is not reflected in a 1:1 translation of protein
expression, the gene product generally follows gene regu-
lation dynamics [19]. A growing number of expression
profiling studies provide experimental evidence indicat-
ing the presence of a transcriptionally distinct gene pat-
tern in MS. Much of our current knowledge of MS stems
from the analysis of a mouse model, experimental
autoimmune encephalomyelitis (EAE) that is thought to
be similar to MS. While EAE has striking clinical and his-
topathological similarities to MS, it has failed in predict-
ing the efficacy of new therapeutics [20]. Our discussion is
largely restricted to those genes that had > 2.5 fold up-reg-
ulation and the two transcription factors that had the
most effect on other genes. Among the total list of differ-
entially expressed genes, the proportion of downregulated
genes was higher than that of upregulated ones (262 vs.
81), an observation that suggests an interplay involving
complex inflammatory cascades in MS.
Study limitations
The findings in our study are limited by a) sample size and
b) the cellular pathways that Epstein-Barr virus (EBV) reg-
ulates remain poorly characterized and there are few data
on how EBV may influence gene pathways in B cells
derived from MS patients vs. controls. The ideal starting
material would be to obtain native B cells from controls
and MS patients; however, collection and processing bias
are hard to eliminate in any microarray-based study.
Upregulated genes
The gene for CXCL10 (interferon-γ-inducible protein-10)
encodes for an interferon (gamma)-induced, secreted pro-
tein of 10 kDa, a chemokine of the CXC subfamily that is
one of the ligands for the receptor CXCR3. The binding of
this protein to CXCR3 causes pleiotropic effects, including
stimulation of monocytes, natural killer and T-cell migra-
tion, and modulation of adhesion molecule expression
(UCSC web browser). Its levels are increased in cerebros-
pinal fluid of MS patients with symptomatic attacks of
demyelination, suggesting a role for this molecule in MS
[21]. Following mouse hepatitis virus (MHV) infection in
mice [22], CXCL10 (IFN inducible protein 10 kDa) pro-
tein was expressed during both acute and chronic stages of
disease suggesting a role for this protein in disease exacer-
Table 5: Relative Expression of Selected Genes by RT-qPCR.
Control MS
RE +/- SD RE SD
TCF2 1.00 0.68 7.95 4.25
CXCL10 1.00 0.47 5.93 3.85
FUT4 1.00 0.43 3.93 2.23
SERPIN B1 1.00 0.57 1.71 1.07
CDC5L 1.00 0.62 0.54 0.26
TNFRSF19 1.00 0.40 0.52 0.28
HLA-DRA 1.00 0.49 0.33 0.16
RE; relative expression.
+/-; calculated by determining relative expression for the value obtained by adding the ∆∆Ct and ∆Ct standard deviation (RE +/-), and then 
subtracting the RE +/- value from the RE.
Table 6: Analysis of SERPINB9, CD83, and CD9 Expression by RT-qPCR.
SERPINB9 CD83 CD9
Pool Indiv Pool Indiv Pool Indiv
C o n t r o l 111111
MS 0.5 2.47 1.1 0.58 1.23 3.5
1. Pool; after RT-qPCR, Control and MS samples pooled prior to calculation of RE by ∆∆Ct method.
2. Indiv; RE of samples first determined by ∆∆CtCt method, then Control and MS sample REs averaged (see text for details).BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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bation and chronicity. Previous studies have shown that
during the acute phase of infection, T lymphocytes are
recruited into the CNS by CXCL10. Our finding that
CXCL10 upregulation (5.8-fold) in B cells from MS sib-
lings is supportive of prior observations.
Serpin B1 is a leukocyte elastase inhibitor and regulates
the activity of the neutrophil proteases elastase, cathepsin
G and proteinase-3. In humans, serpins constitute 10% of
the plasma proteins and are known as critical regulators of
both thrombotic and fibrinolytic systems. Serpins partici-
pate in the regulation of the complement cascade, angio-
genesis, apoptosis and innate immunity. Most of the
human clade B serpins inhibit serine and/or papain-like
cysteine proteinases and protect cells from exogenous and
endogenous proteinase-mediated injury. As some serpins
also guard cells against the deleterious effects of promis-
cuous proteolytic activity [23], it is possible that the cyto-
protective function is a common feature of intracellular
serpin clades and we hypothesize that up-regulation of
serpin B1 gene may be protective in MS. While our find-
ings need to be validated, serpin B1 gene may represent a
novel therapeutic target to ameliorate MS, considering the
importance of these molecules in regulating proteolytic
cascades.
We found that FUT4 gene was upregulated by 2.5 fold. It
is a member of the interleukin 1 cytokine family and the
protein encoded by the gene is produced by activated
macrophages as a pro-protein and processed to its active
form by caspase 1 (CASP1/ICE). This cytokine is an
important mediator of the inflammatory response, cell
proliferation, differentiation, and apoptosis. The induc-
tion of cyclooxygenase-2 (PTGS2/COX2) by this cytokine
in the central nervous system (CNS) is found to contribute
to inflammatory pain hypersensitivity. FUT4 mRNA is
increased in Jurkat cells undergoing apoptosis.
LYPLA3 (lysosomal phospholipase A2): Lysophospholi-
pases are enzymes that act on biological membranes to
regulate the multifunctional lysophospholipids. The pro-
tein encoded by this gene hydrolyzes lysophosphatidyl-
choline to glycerophosphorylcholine and a free fatty acid.
LYPLA3 is present in the plasma and thought to be associ-
ated with high-density lipoprotein. Cellular phospholi-
pases are key participants in cellular transduction [24] and
are thought to be involved in the pathogenesis of local
and systemic inflammatory disorders [25]. Interestingly,
cytosolic phospholipase A2 levels were found to be low,
possibly reflecting proteolysis or inactivation of enzyme
activity in brain MS lesions [26].
The gene for XCL1 was upregulated; it encodes for chem-
okines, a group of small (8-14 kD) molecules that regulate
cell trafficking of leukocytes through interactions with a
subset of 7-transmembrane, G protein-coupled receptors.
Chemokines also play fundamental roles in the develop-
ment, homeostasis, and function of the immune system,
and they have effects on cells of the central nervous system
as well as on endothelial cells involved in angiogenesis or
angiostasis. The protein product of XCL1 has chemotactic
activity for neutrophils may play a role in inflammation
and exerts its effects on endothelial cells in an autocrine
fashion. We also found PSTPIP1 (proline-serine-threo-
nine phosphatase interacting protein1) upregulated; its
role in MS is unclear.
Downregulated genes
An important finding in our study is an 11.7-fold down-
regulation of eukaryotic translation initiation factor 1A, Y-
linked (EIF1AY) gene. It is thought that EIF1AY encodes
for minor histocompatibility antigen (mHA) and B-cell
mediated antibody response to Y-chromosome encoded
histocompatibility antigens (H-Y antigens) is associated
with maintenance of disease remission in graft-vs-host
disease [27]. The B cells may provide a new target for
immune intervention in chronic graft vs. host disease and
whether such a correlation can be translated to chronic
MS requires further study.
We found that the tumor necrosis factor receptor (TNFR)
superfamily 19 gene (TNFRSF 19) was downregulated by
5.3-fold. In a recent study by Achiron et al., TNF super-
family members 14, 1B, 4, and 6 were downregulated. The
TNFR superfamily of cell surface receptors share approxi-
mately 80 amino acids within their cytoplasmic region
called the death domain (DD), critical for recruiting the
death machinery [28]. Individual TNF receptors are
expressed in different cell types and have a range of affin-
ities for various intracellular molecules that provide sign-
aling and biological specificities. However, much is
unknown about how individual signal transduction path-
ways are regulated upon activation by any particular TNF
receptor, under physiological conditions [29] and while
TNFR superfamily 19 genes may mediate important func-
tions in immunity, inflammation, differentiation, cell
proliferation control, and apoptosis, their specific effects
in MS are unknown.
The gene for CD83 was downregulated in MS siblings.
CD83 molecules are expressed at a high level on immune-
competent, activated and mature dendritic cells. In MS,
CD83-positive dendritic cells are present in occasional
perivascular cuffs in lesions, suggesting that mature den-
dritic cells migrate to the CNS in response to chemokine
signals [30].
The downregulation of insulin receptor tyrosine kinase
substrate (BAIAP2L1) gene in B cells of MS siblings is sig-
nificant. The insulin-like growth factor I receptor (IGF-IR),BMC Medical Genomics 2008, 1:2 http://www.biomedcentral.com/1755-8794/1/2
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is a member of the receptor tyrosine kinase family of
growth factor receptors. In rheumatoid arthritis (RA) it
has been shown that IgG antibodies from the sera of
patients can stimulate synovial fibroblasts through inter-
action with insulin-like growth factor receptor 1 (IGF-R1),
provoking trafficking of T cells [31]. The data demon-
strate, for the first time, a bridging link between B-cell
activity and T-cell trafficking. In addition, they are of
potential importance for the development of innovative
therapeutic strategies, in which interrupting the IGF-1/
IGF-1R axis could result in sustained disease modification
by affecting both the growth-factor triggered activation of
fibroblasts and the accumulation of T lymphocytes. A sim-
ilar link in MS has not been demonstrated but is plausible.
Other genes downregulated include ADAMTS16, BID,
MIF and DAPK2, involved in the apoptosis pathway.
TCF2, diabetes and MS
Our transcription and microarray analysis showed that
TCF2 was upregulated. TCF2 encodes transcription factor
2, a liver-specific factor of the homeobox-containing basic
helix-turn-helix family. The TCF2 protein forms het-
erodimers with another liver-specific member of this tran-
scription factor family, TCF1; depending on the TCF2
isoform, activation or inhibition of transcription of target
genes occurs. We found that TCF2 upregulates the CC
chemokine receptor 1 (CCR1) a molecule expressed on
macrophages and T cells; in MS plaques, numerous CCR1-
positive infiltrating macrophages and microglial cells,
associated with CCL3, were found [2] and CCR1 has been
associated with newly infiltrating monocytes in MS
lesions [32]. CCR1-deficient mice show an attenuated
EAE course [33]. Additionally, CXCR1, a pro-inflamma-
tory molecule is upregulated by TCF2. Furthermore, TCF2
downregulated CD28, a co-stimulatory molecule
involved in T-cell stimulation and IL6R, a pro-inflamma-
tory molecule. Taken together, it is plausible that TCF2
plays a central role in the pathogenesis of MS.
Interestingly, a mutation in TCF2 has been linked to the
etiology of MODY5 (Maturity-Onset of Diabetes, Type 5)
and in a recent Danish nationwide cohort study, intra-
individual and, to a lesser degree, intra-familial co-occur-
rence was evident in MS and type 1 diabetes. The underly-
ing mechanisms may involve both genetic and
environmental factors [34]. Individuals with type 1 diabe-
tes are more than three times more likely to develop MS
than controls; in addition, the two diseases appear to be
linked, albeit to a weak extent, within families. The exact
mechanism of how mutations in these transcription fac-
tors cause diabetes remains unknown. To reiterate, a link
between TCF2 mutation and MODY5 has been estab-
lished, while type 1 diabetics have an increased risk of MS
development. Our study points to TCF2 having a promi-
nent role in regulation of other transcription factors. In
summary, the role of TCF2 in MS needs to be further
explored since MODY5 and TCF2 are linked and type 1
diabetes confers increased risk of MS development.
Another transcription factor that we found in our tran-
scription analysis, CDC5L, was downregulated. It is a
well-characterized pre-mRNA splicing factor and involved
in cell cycle kinetics in yeast, S. pombe; its role in MS, if
any, is not characterized.
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